Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA
mutation carriers and wild-type BRCA
pancreatic ductal adenocarcinoma
Authors
Keywords
-
Journal
CANCER
Volume 124, Issue 7, Pages 1374-1382
Publisher
Wiley
Online
2018-01-17
DOI
10.1002/cncr.31218
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
- (2018) Maeve A. Lowery et al. EUROPEAN JOURNAL OF CANCER
- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
- (2017) S. J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
- (2015) J. Bendell et al. ANNALS OF ONCOLOGY
- BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
- (2015) I Lohse et al. BRITISH JOURNAL OF CANCER
- Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma
- (2015) David Fogelman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myelosuppression of Thrombocytes and Monocytes Is Associated with a Lack of Synergy between Chemotherapy and Anti-VEGF Treatment
- (2015) Patrick Starlinger et al. NEOPLASIA
- Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database, 1981–2010
- (2014) Huanhuan Sun et al. Scientific Reports
- Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008
- (2013) L. M. Morton et al. BLOOD
- The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer
- (2013) Mohamed A. Khalil et al. INVESTIGATIONAL NEW DRUGS
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
- (2010) Giuseppe Colucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
- (2009) Shahneen K. Sandhu et al. EUROPEAN JOURNAL OF CANCER
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More